SnagRx Review
Compounded GLP-1 telehealth with low advertised monthly pricing and no separate membership fee.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Quick Verdict
Compounded GLP-1 telehealth with low advertised monthly pricing and no separate membership fee.
Who it's for: SnagRx may appeal to adults focused on a low advertised monthly price for compounded GLP-1 treatment and who prefer no separately listed membership fee. Its public site describes online intake, clinician review, shipping and ongoing support. Because the current $69 and $119 figures are framed as discount pricing, readers should verify whether the rate continues, what dose is included, how refills work and which pharmacy dispenses the prescription. It is not a substitute for FDA-approved Wegovy or Zepbound.
Bottom line: SnagRx is a price-led compounded GLP-1 option with unusually clear advertised inclusions, but its current discounted figures need reconfirmation at checkout. Treat the program as a month-to-month comparator only after verifying the recurring amount and prescription details with the provider.
- No separate membership fee advertised
- Provider review, supplies and shipping described as included
- Published compounded semaglutide and tirzepatide prices
- Advertised figures are presented as a current discount
- Compounded medications are not FDA-approved finished drugs
- Exact pharmacy and state terms should be confirmed
Pros & Cons In Detail
SnagRx Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at SnagRx.
| Program / Membership Fee | Included in published program price |
| Medication Cost (From) | From $69 – $119/mo |
SnagRx advertises compounded semaglutide from $69/month and compounded tirzepatide from $119/month, with provider review, supplies and shipping described as included. Its page presents the figures as a current discount, so confirm the exact starting price, dose, recurring charge, pharmacy and state availability before enrollment.
Who SnagRx Is For
SnagRx may appeal to adults focused on a low advertised monthly price for compounded GLP-1 treatment and who prefer no separately listed membership fee. Its public site describes online intake, clinician review, shipping and ongoing support. Because the current $69 and $119 figures are framed as discount pricing, readers should verify whether the rate continues, what dose is included, how refills work and which pharmacy dispenses the prescription. It is not a substitute for FDA-approved Wegovy or Zepbound.
Adults seeking a lower advertised all-in monthly compounded GLP-1 option without a separate membership fee.
Signature Programs
- ›Compounded semaglutide from a published $69/month
- ›Compounded tirzepatide from a published $119/month
- ›Provider review and telemedicine visits included
- ›No separate membership fee advertised
Medication Formulary
The Bottom Line
SnagRx is a price-led compounded GLP-1 option with unusually clear advertised inclusions, but its current discounted figures need reconfirmation at checkout. Treat the program as a month-to-month comparator only after verifying the recurring amount and prescription details with the provider.
With an editor score of 3.9 / 5 across cost, experience, and trust, SnagRx is one of the specialty options in the glp-1 weight loss category we cover.
See how SnagRx compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss versus 2.4% with placebo at 68 weeks in the STEP 1 trial.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss versus 3.1% with placebo at 72 weeks in SURMOUNT-1.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.
